MedTrace Logo

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT

NCT05943067 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-04-27

No results posted yet for this study

Summary

The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.

Conditions

  • Hematologic Malignancy

Interventions

BIOLOGICAL

CD45RA depleted donor lymphocyte infusion (DLI)

CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Weeks
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2028-01-31
Completion
2028-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05943067 on ClinicalTrials.gov